UroGen Pharma Ownership | Who Owns UroGen Pharma?
UroGen Pharma Ownership Summary
UroGen Pharma is owned by 83.34% institutional investors, 6.86% insiders, and 9.80% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 9.52% of URGN shares. BioPharma Credit Ord is the top mutual fund, with 10.18% of its assets in UroGen Pharma shares.
URGN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | UroGen Pharma | 83.34% | 6.86% | 9.80% |
| Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
| Industry | Biotech Stocks | 306.59% | 11.10% | -217.69% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Rtw investments, lp | 4.54M | 9.52% | $62.25M |
| Toronto dominion bank | 3.19M | 6.68% | $43.71M |
| Blackrock | 2.19M | 6.57% | $36.81M |
| Cowen and company | 2.10M | 6.29% | $35.23M |
| Morgan stanley | 1.84M | 5.51% | $30.85M |
| Blackrock funding, inc. /de | 2.41M | 5.04% | $32.95M |
| Jefferies financial group | 2.20M | 4.61% | $30.14M |
| Soleus capital management | 2.19M | 4.58% | $29.93M |
| Silverarc capital management | 2.02M | 4.24% | $27.71M |
| Menora mivtachim | 1.15M | 2.41% | $15.79M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Silverarc capital management | 2.02M | 5.11% | $27.71M |
| Rosalind advisors | 870.00K | 4.74% | $9.27M |
| Wildcat capital management | 495.61K | 4.03% | $6.79M |
| Soleus capital management | 2.19M | 1.98% | $29.93M |
| Superstring capital management lp | 87.91K | 1.43% | $1.20M |
| Dafna capital management | 349.51K | 1.32% | $4.79M |
| Cowen and company | 2.10M | 0.97% | $35.23M |
| Kynam capital management, lp | 656.57K | 0.97% | $9.00M |
| Rtw investments, lp | 4.54M | 0.89% | $62.25M |
| Tang capital management | 1.00M | 0.69% | $13.70M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Soleus capital management | 2.19M | 1.98% | 2.19M |
| Morgan stanley | 1.84M | 0.00% | 1.45M |
| Toronto dominion bank | 3.19M | 0.07% | 1.44M |
| Jefferies financial group | 2.20M | 0.25% | 1.38M |
| Tang capital management | 1.00M | 0.69% | 1.00M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ubs asset management americas | - | - | -4.36M |
| Ra capital management | - | - | -3.21M |
| Vestal point capital, lp | - | - | -2.15M |
| Nantahala capital management | 6.70K | 0.00% | -1.36M |
| Menora mivtachim | 1.15M | 0.09% | -1.15M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Soleus capital management | 2.19M | 1.98% | 2.19M | $29.93M |
| Tang capital management | 1.00M | 0.69% | 1.00M | $13.70M |
| Rosalind advisors | 870.00K | 4.74% | 870.00K | $9.27M |
| Orbimed advisors | 478.40K | 0.16% | 478.40K | $6.55M |
| Walleye capital | 346.16K | 0.02% | 346.16K | $4.74M |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -4.00 |
| Ifp advisors | -4.00 |
| Signaturefd | -22.00 |
| Coldstream capital management | -29.00 |
| Us bancorp \de\ | -47.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 163 | 13.99% | 39,787,671 | -4.46% | 83 | 1.08% | 84 | 31.25% | 43 | -12.24% |
| Mar 31, 2025 | 143 | 2.14% | 41,643,982 | 14.80% | 87 | 1.24% | 64 | -11.11% | 49 | 25.64% |
| Dec 31, 2024 | 101 | -23.48% | 19,804,522 | -43.62% | 45 | 0.69% | 52 | -30.67% | 26 | -13.33% |
| Sep 30, 2024 | 132 | 9.09% | 35,128,434 | -8.10% | 81 | 0.76% | 75 | -5.06% | 30 | 50.00% |
| Jun 30, 2024 | 120 | 2.56% | 38,225,515 | 40.73% | 114 | 2.03% | 78 | 56.00% | 20 | -45.95% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BioPharma Credit Ord | 4.69M | 10.18% | 4.69M |
| UBS (Lux) Digital Health Equity SB USD | 1.32M | 2.86% | - |
| UBS Lux Dgtl Hlth Eq Fd seeding P acc | 1.25M | 2.71% | - |
| iShares Russell 2000 ETF | 868.93K | 1.88% | -16.48K |
| International Biotechnology Ord | 427.15K | 0.93% | -34.85K |
| Fidelity Small Cap Index | 387.38K | 0.84% | -2.63K |
| iShares Russell 2000 Growth ETF | 264.63K | 0.57% | - |
| State St Russell Sm/Mid Cp® Indx NL Cl C | 262.40K | 0.57% | - |
| State St Russell Sm/Mid Cp® Indx SL Cl I | 262.40K | 0.57% | - |
| iShares Biotechnology ETF | 240.40K | 0.52% | 2.06K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Sep 08, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $16.64K |
| Sep 08, 2025 | Smith Jason Drew | General Counsel | Sell | $29.05K |
| Aug 11, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $176.90K |
| Jul 28, 2025 | Smith Jason Drew | General Counsel | Sell | $143.97K |
| Jul 28, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $98.55K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | 5 |
| 2025 Q2 | - | 1 |
| 2025 Q1 | - | 6 |
| 2024 Q4 | - | - |
| 2024 Q3 | - | 2 |
URGN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools